According to the latest study from BCC Research, "The Global Influenza Market" is expected to grow from $9.0 billion in 2024 ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...